NCT07525908Completed
Efficacy of a Self-Efficacy Nursing Model in CyberKnife-Treated Lung Cancer Patients
Clinical Study on the Impact of a Self-Efficacy Theory-Based Nursing Model on Psychological Distress, Pain Level, and Quality of Life in Lung Cancer Patients Treated With CyberKnife
Source: ClinicalTrials.gov · Last updated 13 Apr 2026
Brief summary (registry, in English)
This study evaluates whether a multi-component nursing model based on self-efficacy theory can alleviate psychological distress, mitigate pain, and improve the quality of life (QoL) in lung cancer patients undergoing CyberKnife stereotactic radiosurgery compared to routine nursing care.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 300 (actual)
- First submitted
- 6 Apr 2026
- Start date
- 1 Oct 2023
- Primary completion date
- 31 Oct 2024
- Lead sponsor
- The First Hospital of Hebei Medical University
- Diseases
- Lung cancer
- NCT number
- NCT07525908
What you commit to
- Study type: Interventional
- Participants enrolled: 300
- From 1 Oct 2023 to the primary completion date, 31 Oct 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous radiotherapy to the planned CyberKnife treatment field.
- Participation in another interventional clinical trial concurrently or within 30 days prior to enrollment.
Other illness
- Presence of severe, uncontrolled cardiovascular, cerebrovascular, respiratory, hepatic, or renal diseases.
- Known history of severe psychiatric disorders or cognitive impairment.
- Presence of other active malignancies requiring systemic treatment.
- Known severe, uncontrolled endocrine or metabolic diseases.
- Significant coagulation disorders.
Who the study is looking for
- Aged between 40 and 80 years, inclusive.
- Histologically or cytologically confirmed diagnosis of primary lung cancer (suitable for CyberKnife treatment).
- Scheduled to receive CyberKnife stereotactic radiosurgery as a primary or palliative treatment.
- Karnofsky Performance Status (KPS) score of 80-100.
- Patient-Generated Subjective Global Assessment (PG-SGA) score ≤ 5.
- Estimated life expectancy of at least 6 months.
- Able to understand, speak, and read Mandarin Chinese.
- Willing and able to provide written informed consent.
Age in the registry: 40 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| First Hospital of Hebei Medical University Coordinator of this site? Confirm its status | Shijiazhuang | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.